A rival to Botox
-
[FDA Approves New Botox Rival](link url)
The U.S. Food and Drug Administration approved a new antiwrinkle treatment that could be the most formidable challenger to date to market leader Botox.
For about two decades, Botox, now sold by AbbVie Inc., has dominated the aesthetic-drug market it helped pioneer, racking up tens of billions of dollars in sales and successfully fending off challengers.
The FDA’s approval of Revance Therapeutics Inc.’s Daxxify introduces a new rival that doctors and analysts said could succeed carving out a big slice of a lucrative and fast-growing market by promising to last two months longer than Botox’s four months.
The FDA approved Daxxify, also known as daxibotulinumtoxinA, for the temporary improvement of frown lines in adults, Revance said Thursday.
The decision, analysts and doctors said, should touch off a fierce battle between upstart Revance and industry giant AbbVie, which acquired Botox as the centerpiece of a $63 billion deal for its manufacturer in 2020.
“This marks what we think is the first real competitive threat to Botox,” said Cowen Inc. analyst Ken Cacciatore, who expects Daxxify to generate $1 billion in sales as early as 2030.
-
I was talking with my BIL last weekend. Botox is in no trouble with this, as it is in clinical trials for quite a number of other uses, including migraines, bladder problems, etc. It is apparently doing well in many. Miracle drug.
https://www.centerwatch.com/clinical-trials/listings/treatment/454/botox/
.
-
Problem with Botox cosmetically, is once you start, you have to keep it up.
-
@jon-nyc said in A rival to Botox:
I was at a party last weekend and the hostess had gone a bit far with her lips.
So many punchlines, so little time.
